Insight Molecular Diagnostics R&D Spending Growth & History (IMDX)
Insight Molecular Diagnostics's r&d spending was $15.9M for fiscal 2025.
View full Insight Molecular Diagnostics company overviewInsight Molecular Diagnostics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $15.9M | $6.1M | +61.60% |
| 2024 | 2024-12-31 | $9.8M | $545,000 | +5.86% |
| 2023 | 2023-12-31 | $9.3M | $2.0M | +27.30% |
| 2022 | 2022-12-31 | $7.3M | $2.3M | +45.00% |
| 2021 | 2021-12-31 | $5.0M | −$4.8M | −48.62% |
| 2020 | 2020-12-31 | $9.8M | $3.0M | +44.24% |
| 2019 | 2019-12-31 | $6.8M | $280,000 | +4.30% |
| 2018 | 2018-12-31 | $6.5M | −$660,000 | −9.20% |
| 2017 | 2017-12-31 | $7.2M | $1.5M | +26.37% |
| 2016 | 2016-12-31 | $5.7M | $1.1M | +25.40% |
| 2015 | 2015-12-31 | $4.5M | $565,000 | +14.26% |
| 2014 | 2014-12-31 | $4.0M | — | — |
Insight Molecular Diagnostics quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.5M | $1.2M | +37.23% |
| Q1 2026 | 2026-03-31 | $5.0M | $2.0M | +69.39% |
| Q4 2025 | 2025-12-31 | $5.8M | $3.6M | +158.26% |
| Q3 2025 | 2025-09-30 | $3.9M | $1.1M | +37.66% |
| Q2 2025 | 2025-06-30 | $3.3M | $816,000 | +33.27% |
| Q1 2025 | 2025-03-31 | $2.9M | $612,000 | +26.47% |
| Q4 2024 | 2024-12-31 | $2.3M | −$290,000 | −11.39% |
| Q3 2024 | 2024-09-30 | $2.8M | $632,000 | +28.92% |
| Q2 2024 | 2024-06-30 | $2.5M | $18,000 | +0.74% |
| Q1 2024 | 2024-03-31 | $2.3M | $185,000 | +8.70% |
| Q4 2023 | 2023-12-31 | $2.5M | $1.2M | +84.83% |
| Q3 2023 | 2023-09-30 | $2.2M | $713,000 | +48.44% |
| Q2 2023 | 2023-06-30 | $2.4M | −$9,000 | −0.37% |
| Q1 2023 | 2023-03-31 | $2.1M | $120,000 | +5.98% |
| Q4 2022 | 2022-12-31 | $1.4M | −$3.2M | −69.98% |
| Q3 2022 | 2022-09-30 | $1.5M | −$1.7M | −53.15% |
| Q2 2022 | 2022-06-30 | $2.4M | −$93,000 | −3.67% |
| Q1 2022 | 2022-03-31 | $2.0M | −$1.4M | −40.29% |
| Q4 2021 | 2021-12-31 | $4.6M | $2.8M | +155.06% |
| Q3 2021 | 2021-09-30 | $3.1M | $527,000 | +20.15% |
| Q2 2021 | 2021-06-30 | $2.5M | −$688,000 | −21.33% |
| Q1 2021 | 2021-03-31 | $3.4M | $1.2M | +55.67% |
| Q4 2020 | 2020-12-31 | $1.8M | −$518,000 | −22.35% |
| Q3 2020 | 2020-09-30 | $2.6M | $990,000 | +60.92% |
| Q2 2020 | 2020-06-30 | $3.2M | $1.7M | +113.86% |
| Q1 2020 | 2020-03-31 | $2.2M | $816,000 | +60.76% |
| Q4 2019 | 2019-12-31 | $2.3M | $1.1M | +92.52% |
| Q3 2019 | 2019-09-30 | $1.6M | $98,000 | +6.42% |
| Q2 2019 | 2019-06-30 | $1.5M | −$814,000 | −35.06% |
| Q1 2019 | 2019-03-31 | $1.3M | −$118,000 | −8.08% |
| Q4 2018 | 2018-12-31 | $1.2M | −$303,000 | −20.11% |
| Q3 2018 | 2018-09-30 | $1.5M | −$309,000 | −16.83% |
| Q2 2018 | 2018-06-30 | $2.3M | $325,000 | +16.27% |
| Q1 2018 | 2018-03-31 | $1.5M | −$373,000 | −20.34% |
| Q4 2017 | 2017-12-31 | $1.5M | $77,000 | +5.38% |
| Q3 2017 | 2017-09-30 | $1.8M | $473,000 | +34.70% |
| Q2 2017 | 2017-06-30 | $2.0M | $802,000 | +67.11% |
| Q1 2017 | 2017-03-31 | $1.8M | $145,000 | +8.58% |
| Q4 2016 | 2016-12-31 | $1.4M | $0 | 0.00% |
| Q3 2016 | 2016-09-30 | $1.4M | $269,000 | +24.59% |
| Q2 2016 | 2016-06-30 | $1.2M | $309,000 | +34.88% |
| Q1 2016 | 2016-03-31 | $1.7M | $572,000 | +51.21% |
| Q4 2015 | 2015-12-31 | $1.4M | — | — |
| Q3 2015 | 2015-09-30 | $1.1M | — | — |
| Q2 2015 | 2015-06-30 | $886,000 | — | — |
| Q1 2015 | 2015-03-31 | $1.1M | — | — |
Insight Molecular Diagnostics r&d spending trends
Over the last five fiscal years, Insight Molecular Diagnostics's r&d spending increased from $9.8M to $15.9M, a change of $6.1M. The latest reported quarter, Q2 2026, shows $4.5M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Insight Molecular Diagnostics source filings ↗